Q-omics provides the consensus-scored UBE2V1P6 profile across patient tissues and cancer cell-line models. UBE2V1P6 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, UBE2V1P6 is differentially expressed in 1, with the highest sampling consensus in KIRC. Additionally, UBE2V1P6 RNA expression shows 5,415 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight SKCM, KIRC, and STAD as cancer lineages where UBE2V1P6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBE2V1P6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBE2V1P6 survival associations across molecular data types. UBE2V1P6 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBE2V1P6 RNA expression–survival associations across cancer types. High UBE2V1P6 expression shows unfavorable associations in THYM, MESO, STAD and LUAD, but favorable associations in SKCM and ESCA. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify SKCM as the clearest survival context for UBE2V1P6 RNA expression.
This table summarizes UBE2V1P6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for UBE2V1P6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBE2V1P6 shows higher tumor expression in KIRC. The KIRC box plot shows higher UBE2V1P6 RNA expression in tumor versus normal tissue (log2 FC = +0.014, t-test p = .022).
This table shows molecular features associated with UBE2V1P6 in patient tissues and cancer cell lines. In patient samples, UBE2V1P6 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
